DERA by Directed Evolution

After screening about 10000 individual variant clones, more than 60 primary hit clones with more than 50% increased stability were selected and recombined using a proprietary recombination method [28]. After two rounds of recombination and screening with increased CIAA concentrations, ten clones were selected for retesting on shake-flask scale. 

6 The Development of Short, Efficient, Economic, and Sustainable Chemoenzymatic Processes 

Several efficient biocatalytic processes to statin side chain intermediates have been developed in the last two decades, and all have their characteristic advantages and 

together with the short synthetic route starting from simple and cheap raw materials and the applicability of the DERA product as a common statin building block, makes the DERA process one of the economically most attractive routes for the manufacture of statin side chain intermediates. 

We gratefully acknowledge the contributions and support of our colleagues Daniel Mink, Theo Sonke, and Marcel Wubbolts. 

---